177Lu Radiolabeling of RM26 Modified with Oligo-Phenylene-Ethynylene and its Cellular Internalization

177Lu Radiolabeling of RM26 Modified with Oligo-Phenylene-Ethynylene and its Cellular Internalization

Gastrin releasing peptide receptor (GRPR) is overexpressed in various tumors, and these GRPR-positive tumors have successfully and widely been targeted with GRPR antagonists. To achieve a good therapeutic effectiveness and less radioactive dosage administration, high cellular internalization is requ...

Full description

Bibliographic Details
Main Author:	LIAO Wei;FU Huaxia;LI Xiangyu;KAN Wentao;YANG Xia;WANG Jing;ZHAO Peng;ZHUO Liangang;YANG Yuchuan;WEI Hongyuan
Format:	Article
Language:	zho
Published:	Editorial Board of Journal of Isotopes 2022-06-01
Series:	Journal of Isotopes
Subjects:	177lu rm26 peptide oligo-phenylene-ethynylene internalization
Online Access:	http://www.tws.org.cn/CN/10.7538/tws.2022.35.03.0200

Similar Items

Coupling Reaction of Oligo p-Phenylene Ethynylene and Peptide Antagonist RM26 Labeling with 131
by: JIAN Yuan1,2;ZHOU Zhi-jun2;ZHUO Lian-gang2;ZHAO Peng2;LIAO Wei2;WANG Guan-quan2;LIU Ning1
Published: (2016-08-01)

X-ray spectroscopy characterization of self-assembled monolayers of nitrile-substituted oligo(phenylene ethynylene)s with variable chain length
by: Hicham Hamoudi, et al.
Published: (2012-01-01)

Efficient synthesis of phenylene-ethynylene rods and their use as rigid spacers in divalent inhibitors
by: Francesca Pertici, et al.
Published: (2013-01-01)

The Recent Research Development of 177Lu Radiopharmaceuticals
by: YANG Yuchuan;KAN Wentao;YANG Xia;WEI Hongyuan;ZHUO Liangang;WANG Jing;LIAO Wei;ZHAO Peng;WANG Guanquan
Published: (2022-06-01)

Preparation of No-Carrier-Added 177Lu by DGA Resin Assisted Cyclic Elution
by: ZHUO Liangang;YANG Yuchuan;YUE Haidong;XIONG Xiaoling;WANG Guanquan;WANG Hailin;YANG Lin;LIN Qingchuan;CHEN Qiping;TU Jun;WEI Hongyuan
Published: (2022-06-01)

Glycosylated Oligo(ethynylene)s via a Pd/Zn-Mediated Cross-Coupling Reaction
by: Tobias N. Hoheisel, et al.
Published: (2009-04-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery
by: Else A. Aalbersberg, et al.
Published: (2022-09-01)

Evaluation of carrier added (CA) and no carrier added (NCA) 177Lu radionuclide roles in radiolabeling of peptide groups
by: S. Vosoughi, et al.
Published: (2020-11-01)

Production of Carrier Added 177Lu in HFETR
by: HU Yingjiang;WANG Lei;WU Jianrong;LI Bo;LUO Ning;CHEN Yunming;ZENG Junjie;SUN Zhizhong;JIA Zhijun;ZHANG Jinsong
Published: (2023-02-01)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
by: Peter Frøhlich Staanum, et al.
Published: (2021-11-01)

On the feasibility of producing Lu-177 in the IEA-R1 reactor via the direct route
by: Guilherme Soares Zahn, et al.
Published: (2021-04-01)

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
by: Madhav Prasad Yadav, et al.
Published: (2019-02-01)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Rosalba Mansi, et al.
Published: (2021-12-01)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
by: Frederik A. Verburg, et al.
Published: (2023-11-01)

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [177Lu]Lu-PSMA
by: Eline L. Hooijman, et al.
Published: (2022-11-01)

Dealing with dry waste disposal issues associated with 177mLu impurities: a long-term challenge for nuclear medicine departments
by: Sylviane Prevot, et al.
Published: (2023-01-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE
by: Teresa Monserrat Fuertes, et al.
Published: (2023-09-01)

Extravasation of [177Lu]Lu-DOTATOC: case report and discussion
by: Anne Kirstine Arveschoug, et al.
Published: (2020-06-01)

Improved quality control of [177Lu]Lu-PSMA I&T
by: Martin Kraihammer, et al.
Published: (2023-03-01)

Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
by: Sejin Ha, et al.
Published: (2024-02-01)

[177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
by: Madhav Prasad Yadav, et al.
Published: (2020-10-01)

Anatomy-based correction of kidney PVE on $$^{177}\text{Lu}$$ 177 Lu SPECT images
by: Julien Salvadori, et al.
Published: (2024-02-01)

An exceptional response to 177LuPSMA undermined by neuroendocrine transformation
by: Pretoria Bilinski, et al.
Published: (2021-01-01)

Preparation and Preliminary Biological Evaluation of 177Lu Labelled Rituximab
by: MA Xiu-feng1;ZHANG Jun-li2;LI Hong-yu1,2;LIANG Ji-xin1;YANG Yun2;YANG Chun-hui2;DU Jin1,3
Published: (2014-02-01)

Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives
by: Rahaf Alsadi, et al.
Published: (2022-07-01)

Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry
by: Mercedes Riveira-Martin, et al.
Published: (2023-11-01)

Evaluation of Human Absorbed Dose of 177Lu-DOTA-Trastuzumab Based on its Biodistribution Studies in Rats
by: A Bahrami-Samani, et al.
Published: (2016-08-01)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours
by: Pascale Plas, et al.
Published: (2022-08-01)

Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
by: Mikhail Rumiantcev, et al.
Published: (2023-09-01)

Peptide Receptor Radionuclide Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
by: Maria I. del Olmo-García, et al.
Published: (2022-01-01)

Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand ［177Lu］Lu-DOTA-CPN-PSMA
by: LUO Tian-wei, et al.
Published: (2023-12-01)

Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
by: Jill Wevrett, et al.
Published: (2018-08-01)

Acquisition Conditions for Lu-177 DOTATATE Imaging
by: Yuri Sagisaka, et al.
Published: (2024-01-01)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi and [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>
by: Sanjana Ballal, et al.
Published: (2021-11-01)

Tumor dosimetry using 177Lu: influence of background activity, measurement method and reconstruction algorithm
by: Peter Frøhlich Staanum
Published: (2023-06-01)

Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
by: Sarah Boughdad, et al.
Published: (2022-12-01)

Research Progress of 177Lu-DOTATATE in the Treatment of Neuroendocrine Tumor Patients with Environmental Radiation Safety
by: MA Guangyu;BA Jiantao;PENG Cheng;CHEN Yingmao
Published: (2022-04-01)

Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
by: Matthew Glover, et al.
Published: (2021-11-01)